Centene Corporation
CNC
$62.22
+2.27%
Centene Corporation is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and individual exchanges. As a leading provider in the managed care industry, Centene serves approximately 20 million medical members, with a strong emphasis on Medicaid and individual exchange plans. The current investor narrative centers on the company's strategic pivot toward profitability following a significant loss in Affordable Care Act membership, which has led to cost-cutting measures such as voluntary staff buyouts. Additionally, recent positive developments in Medicare Advantage payment rates from CMS have boosted sector sentiment and revenue visibility.…
CNC
Centene Corporation
$62.22
Related headlines
Investment Opinion: Should I buy CNC Today?
Rating: Hold. Centene is a speculative turnaround play with improving fundamentals but significant execution risk. The consensus analyst rating is Buy with an average target of $65.17, implying modest upside, but the wide target range and recent volatility warrant caution.
Supporting Evidence: The P/S ratio of 0.10x is deeply discounted versus historical averages (0.32x-1.48x) and peers, suggesting value. Revenue growth of 7.13% YoY is solid, and the return to profitability with a 3.09% net margin in Q1 2026 is encouraging. Free cash flow of $6.35 billion TTM provides financial flexibility. However, the negative trailing EPS and net margin highlight that the turnaround is incomplete. The forward P/E of 14.17x implies earnings recovery is priced in, leaving limited upside if expectations are met.
Risks & Conditions: The biggest risks are a failure to sustain profitability, membership losses, and regulatory headwinds. This Hold would upgrade to Buy if the stock pulls back to $50 (near the low end of analyst targets) or if net margins consistently exceed 3% for two quarters. A downgrade to Sell would be warranted if revenue growth decelerates below 5% or if the company reports another quarterly loss. Overall, Centene appears fairly valued relative to its near-term earnings potential but undervalued on a sales basis; the market is pricing in a successful turnaround, but the risk of disappointment remains high.
Sign up to view all
CNC 12-Month Price Forecast
Centene's outlook is balanced between a successful turnaround and continued challenges. The deeply discounted P/S ratio provides a valuation floor, but the negative trailing earnings and wide analyst target range highlight uncertainty. The base case of modest upside to $65 is most likely, but the stock could swing 20% in either direction depending on profitability trends. A neutral stance is warranted given the risk-reward symmetry. Upgrades to bullish would require consistent margin expansion above 3%; downgrades to bearish would follow any quarterly loss.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Centene Corporation's 12-month outlook, with a consensus price target around $70.67 and implied upside of +13.6% versus the current price.
Average Target
$70.67
0 analysts
Implied Upside
+13.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$56 - $85
Analyst target range
Centene is covered by 18 analysts, with a consensus recommendation of 'Buy' (mean recommendation of 2.48 on a scale where 1 is Strong Buy and 5 is Sell). The average target price is $65.17, implying an upside of approximately 2.8% from the current price of $63.41. The distribution shows a bullish leaning, with recent ratings from firms like B of A Securities (Buy), Truist Securities (Buy), and Barclays (Overweight), while others like JP Morgan and Mizuho maintain Neutral stances. The target price range spans from a low of $40.00 to a high of $80.00. The high target of $80.00 assumes a successful turnaround with margin expansion and membership stabilization, potentially driven by the Medicare Advantage tailwind. The low target of $40.00 prices in continued membership losses and margin compression. The wide spread ($40 to $80) indicates high uncertainty about the company's future performance. Recent analyst actions have been largely neutral to positive, with no downgrades in the past two months, suggesting a stable outlook. The consensus implies modest upside, reflecting cautious optimism.
Drowning in data?
Find the real signal!
Bulls vs Bears: CNC Investment Factors
Centene presents a classic turnaround story with strong revenue growth and a return to profitability in Q1 2026, but the trailing twelve-month losses and membership challenges introduce significant risk. The bull case is anchored by a deeply discounted P/S ratio of 0.10x, positive analyst consensus, and robust free cash flow, while the bear case highlights negative earnings, wide analyst target dispersion, and the stock's proximity to its 52-week high. The single most important tension is whether Centene can sustain its profitability improvement—if net margins stabilize above 3%, the stock could re-rate significantly; if losses recur, the stock could fall back toward the $40 low target. Currently, the evidence slightly favors the bulls given the valuation discount and improving fundamentals, but the risk-reward is balanced.
Bullish
- Strong Revenue Growth: Revenue grew 7.13% YoY to $49.94 billion in Q1 2026, with consistent sequential growth from $40.81 billion in Q4 2024. This demonstrates the company's ability to expand its top line despite membership challenges.
- Return to Profitability: Net income swung from a loss of $1.10 billion in Q4 2025 to a profit of $1.54 billion in Q1 2026, with net margin improving to 3.09%. This turnaround is a key catalyst for the stock's 137% one-year gain.
- Deeply Discounted Valuation: The P/S ratio of 0.10x is near the bottom of its historical range (0.32x to 1.48x) and well below typical managed care peers (0.5x-1.0x). This suggests significant upside if the turnaround continues.
- Positive Analyst Sentiment: 18 analysts rate the stock a consensus Buy with an average target of $65.17, implying 2.8% upside. The high target of $80.00 offers 26% upside, reflecting optimism on margin expansion and Medicare Advantage tailwinds.
Bearish
- Negative Trailing Earnings: Trailing twelve-month EPS is -$0.33, and net margin is -3.43%. The company has reported losses in three of the last four quarters, indicating inconsistent profitability.
- Membership Slump and Cost Cuts: A significant loss in ACA membership has forced Centene into voluntary staff buyouts, signaling near-term revenue pressure. This operational disruption could hamper growth.
- High Uncertainty in Targets: Analyst targets range from $40.00 to $80.00, a 100% spread, reflecting extreme uncertainty. The low target implies 37% downside from the current price of $63.41.
- Near 52-Week High: The stock trades at $63.41, 91.4% of its 52-week high of $69.36. After a 137% rally in one year, the stock may be overextended and vulnerable to profit-taking.
CNC Technical Analysis
Centene's stock is in a strong uptrend, with a 1-year price change of +136.96%, significantly outperforming the S&P 500's 16.47% gain. The current price of $63.41 is trading at 91.4% of its 52-week range ($25.08 to $69.36), indicating the stock is near its highs and reflecting strong momentum. This positioning near the top of the range suggests bullish sentiment but also potential overextension in the near term. The stock has recovered sharply from its 52-week low of $25.08, which was set in March 2026, and is now approaching its 52-week high of $69.36. The 1-month price change is +69.87%, while the 3-month change is +51.63%, both showing accelerating momentum. This short-term strength aligns with the longer-term uptrend, confirming a robust bullish phase. The 1-month relative strength versus the S&P 500 is -8.13%, indicating slight underperformance recently, but the 3-month relative strength of +48.13% underscores strong outperformance over the past quarter. The 52-week low of $25.08 provides key support, while the 52-week high of $69.36 acts as resistance. A breakout above $69.36 would signal continued upside and potentially target new highs, while a breakdown below $25.08 would be a severe bearish reversal. The beta of 1.077 indicates the stock is slightly more volatile than the market, meaning it tends to amplify market moves, which is important for risk management.
Beta
1.08
1.08x market volatility
Max Drawdown
-55.5%
Largest decline past year
52-Week Range
$25-$69
Price range past year
Annual Return
+138.7%
Cumulative gain past year
| Period | CNC Return | S&P 500 |
|---|---|---|
| 1m | -9.0% | +0.2% |
| 3m | +16.6% | +3.7% |
| 6m | +43.6% | +8.0% |
| 1y | +138.7% | +18.2% |
| ytd | +48.9% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CNC Fundamental Analysis
Centene's revenue trajectory shows steady growth, with the most recent quarterly revenue (Q1 2026) at $49.94 billion, up 7.13% year-over-year. Over the past four quarters, revenue has grown from $40.81 billion (Q4 2024) to $49.94 billion, indicating a consistent upward trend. The revenue segments are dominated by Medicaid ($39.21 billion), followed by Commercial ($9.56 billion) and Other ($1.18 billion), with Medicaid being the primary growth driver. The company's profitability has been volatile, with net income in Q1 2026 of $1.54 billion, a significant improvement from losses in the prior two quarters (Q4 2025: -$1.10 billion, Q3 2025: -$6.63 billion). Gross margin in Q1 2026 was 21.9%, up from 15.2% in Q4 2025 and 6.0% in Q2 2025, showing margin expansion. However, the trailing twelve-month net margin is -3.43%, reflecting the impact of prior losses. The company is now profitable on a quarterly basis, with a net income ratio of 3.09% in Q1 2026. Centene's balance sheet shows a debt-to-equity ratio of 0.94, which is moderate but manageable. The current ratio of 1.68 indicates adequate liquidity. Free cash flow (TTM) is $6.35 billion, with Q1 2026 free cash flow of $3.40 billion, demonstrating strong cash generation. ROE is negative at -33.44% due to the accumulated losses, but the improving profitability trend suggests a potential turnaround. The company does not pay dividends, focusing on reinvestment and debt reduction.
Quarterly Revenue
$49.9B
2026-03
Revenue YoY Growth
+7.1%
YoY Comparison
Gross Margin
21.9%
Latest Quarter
Free Cash Flow
$6.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CNC Overvalued?
Since Centene's trailing twelve-month net income is negative (EPS of -$0.33), the trailing P/E ratio is not meaningful. Therefore, we use the price-to-sales (P/S) ratio as the primary valuation metric. The trailing P/S ratio is 0.10x, while the forward P/E is 14.17x, indicating that the market expects a return to profitability. The gap between the negative trailing P/E and positive forward P/E implies strong earnings growth expectations. Compared to the industry average (not provided, but typically for managed care companies, P/S ratios range from 0.5x to 1.0x), Centene's P/S of 0.10x appears deeply discounted. This discount likely reflects the recent losses and membership challenges, but it also suggests potential value if the turnaround materializes. The EV/Sales ratio of 0.14x further supports a low valuation relative to sales. Historically, Centene's P/S ratio has ranged from 0.32x (Q1 2026) to 1.48x (Q4 2021). The current P/S of 0.10x is near the bottom of its historical range, indicating that the stock is trading at a significant discount to its own history. This could represent a value opportunity if the company's fundamentals improve, but it also signals that the market is pricing in considerable risk.
PE
-3.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 3x~27x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-4.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Centene's recent profitability has been volatile, with net losses in Q3 and Q4 2025 totaling $7.73 billion, followed by a $1.54 billion profit in Q1 2026. The negative trailing net margin of -3.43% and ROE of -33.44% indicate that the company is still recovering from significant operational challenges. The debt-to-equity ratio of 0.94 is moderate, but the negative equity base (due to losses) could amplify leverage risks. Free cash flow of $6.35 billion provides a cushion, but the reliance on cost-cutting measures like staff buyouts to restore profitability may not be sustainable long-term. Revenue concentration in Medicaid (78% of Q1 2026 revenue) exposes the company to government funding changes and membership fluctuations.
Market & Competitive Risks: The stock's beta of 1.077 indicates slightly higher volatility than the market, making it sensitive to macro shifts. The P/S ratio of 0.10x is deeply discounted, but this could reflect market skepticism about the turnaround's durability. Competitive pressures from larger players like UnitedHealth and Humana, along with regulatory risks from CMS payment adjustments, are significant. The recent positive CMS Medicare Advantage payment increase has boosted sector sentiment, but any reversal could hurt margins. The stock's 137% one-year gain has outpaced the S&P 500 by 120 percentage points, raising the risk of mean reversion.
Worst-Case Scenario: If Centene fails to sustain profitability and membership losses accelerate, the stock could retest its 52-week low of $25.08, representing a 60% decline from the current price of $63.41. This scenario could be triggered by a reversal in Medicaid enrollment, adverse regulatory changes, or a return to negative net income. The analyst low target of $40.00 implies a 37% downside, which is a more moderate but still severe risk. Historical max drawdown of -55.5% suggests that significant losses are possible in adverse conditions.
FAQ
The primary risk is execution risk: Centene must sustain its return to profitability after a volatile period of losses. The negative trailing net margin of -3.43% and ROE of -33.44% highlight the fragility of its earnings. Second, membership concentration in Medicaid (78% of revenue) exposes the company to government funding cuts or enrollment declines. Third, the stock's beta of 1.077 and 137% one-year gain mean it could be vulnerable to profit-taking or market downturns. Finally, the wide analyst target range ($40-$80) reflects high uncertainty, and the low target implies 37% downside from the current price. The most severe risk is a return to quarterly losses, which could drive the stock back toward its 52-week low of $25.08.
The 12-month forecast is balanced across three scenarios. The base case (50% probability) sees the stock trading near the analyst average target of $65.17, assuming sustained profitability and moderate growth. The bull case (25% probability) targets $70-$80, driven by margin expansion and Medicare Advantage tailwinds. The bear case (25% probability) sees the stock falling to $40-$50 if profitability deteriorates. The most likely outcome is the base case, with the stock hovering around $65, but the wide range reflects high uncertainty. Key assumptions include net margins stabilizing above 2% and revenue growth of 5-7%.
Centene appears undervalued based on sales, with a P/S ratio of 0.10x versus its historical range of 0.32x to 1.48x and typical managed care peers at 0.5x-1.0x. This deep discount suggests the market is pricing in significant risk, including the negative trailing net margin of -3.43% and membership losses. On a forward earnings basis, the P/E of 14.17x implies that the market expects a return to profitability, which is not yet confirmed. Relative to its own history, the stock is cheap on sales but expensive relative to its recent earnings power. Overall, the valuation is fair given the uncertainty, but it could be considered undervalued if the turnaround succeeds.
Centene offers a compelling risk-reward for investors who believe in its turnaround story. The stock trades at a P/S ratio of 0.10x, near historical lows and well below managed care peers, suggesting significant upside if profitability improves. The analyst consensus is Buy with an average target of $65.17, implying 2.8% upside, but the high target of $80.00 offers 26% upside. However, the trailing EPS is negative (-$0.33), and the company has reported losses in three of the last four quarters. For risk-tolerant investors with a 12-month horizon, CNC could be a good buy on pullbacks near $55, but it is not suitable for conservative investors seeking stable returns.
Centene is best suited for a medium-term investment horizon of 12-24 months, as the turnaround story requires time to play out. The stock's beta of 1.077 and recent 137% rally make it volatile for short-term trading, but the deep valuation discount could reward patient investors. Long-term holding is risky due to the negative trailing earnings and membership challenges, but if the turnaround succeeds, the stock could re-rate significantly. The company does not pay a dividend, so it is not suitable for income-focused investors. A minimum holding period of 12 months is recommended to allow for earnings improvement and catalyst realization.
